Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Evaluation of Fluoxetine in Refractory Constipation Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Yang Bin
- Target Recruit Count
- 116
- Registration Number
- NCT06506136
Fluoxetine in KCNC1-related Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT06341127
- Locations
- 🇨🇦
Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada
Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT06225011
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 150
- Registration Number
- NCT06221722
- Locations
- 🇨🇳
People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China
🇨🇳Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China
🇨🇳Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 200
- Registration Number
- NCT06046859
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 520
- Registration Number
- NCT05814640
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
- Conditions
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT05634707
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States
Fluoxetine Treatment of Depression in Down Syndrome
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT05458479
- Locations
- 🇺🇸
Lurie Center for Autism, Lexington, Massachusetts, United States
Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Michigan State University
- Target Recruit Count
- 6
- Registration Number
- NCT05378711
- Locations
- 🇺🇸
Michigan State University Psychiatry Clinic, East Lansing, Michigan, United States
A Multicenter Clinical Study on Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Peking University
- Target Recruit Count
- 160
- Registration Number
- NCT05361330
- Locations
- 🇨🇳
Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳First Hospital, Shanxi Medical University, Taiyuan, Shanxi, China
🇨🇳Institute of Mental Health, Peking University Sixth Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.